BRTO, short for Balloon-Occluded Retrograde Transvenous Obliteration, is a minimally invasive endovascular treatment designed to manage gastric varices, often arising from portal hypertension. This article explains what BRTO is, how the procedure works, indications, risks, recovery, and outcomes. The goal is to provide a clear, evidence-based overview for readers seeking practical information about this therapy and its role in preventing life-threatening bleeding from varices.
What Is BRTO And When Is It Used
BRTO is a specialized procedure that targets gastric varices by occluding a portosystemic shunt and obliterating the variceal veins from within the venous system. It uses a balloon catheter introduced through a systemic vein, typically accessed via the leg or neck, to reach the gastrorenal shunt. By securing the shunt and injecting sclerosant into the variceal complex, BRTO reduces the pressure driving variceal bleeding. This technique is particularly relevant for patients with noncirrhotic portal hypertension or portal hypertension with large gastric varices and minimal ascites.
How BRTO Works: Anatomical Targets And Mechanism
The procedure relies on identifying a gastrorenal or gastro-renal portosystemic shunt that connects gastric varices to the left renal vein. The balloon catheter temporarily occludes the shunt and creates a static blood pool within the variceal plexus. A sclerosant agent is then injected to induce thrombosis and sclerosis of the varices, effectively sealing off abnormal blood flow. After sclerosant dwell time, the balloon is deflated and removed, leaving a obliterated venous channel. This reduces the risk of recurrent bleeding by diverting portal blood away from the variceal network.
Before BRTO: Evaluation And Preparation
Prior to BRTO, a thorough evaluation ensures suitability and safety. Key steps include noninvasive imaging, such as Doppler ultrasound and CT or MRI venography, to map the portosystemic shunt and variceal anatomy. Laboratory tests assess liver function, blood clotting, and overall health. A multidisciplinary team—interventional radiology, hepatology, and anesthesia—reviews risk factors and plans anesthesia, access route, and sclerosant choice. Patients may undergo temporary portal vein pressure assessment to estimate bleeding risk and post-procedure expectations.
BRTO Procedure: Step-By-Step Overview
The BRTO process is performed under imaging guidance, typically in an interventional radiology suite. The general sequence is as follows:
- Vascular Access: A venous access point is established, commonly via the femoral or jugular vein.
- Catheter Navigation: A catheter with a deflated balloon is advanced to the gastrorenal shunt under fluoroscopic guidance.
- Balloon Occlusion: The balloon is inflated to occlude the shunt, creating a stagnant pool in the gastric varices.
- Sclerosant Delivery: A sclerosant, such as ethanolamine oleate or another agent, is infused into the variceal network and left to dwell for a prescribed period.
- Thrombosis And Obliteration: The sclerosant promotes thrombosis and sclerosis of the varices, sealing off abnormal flow paths.
- Balloon Removal And Confirmation: The balloon is deflated and withdrawn. Post-procedure imaging confirms obliteration and evaluates for collateral flow.
- Recovery and Monitoring: The patient is monitored for complications and instructed on post-procedural care.
Benefits And Risks Of BRTO
BRTO offers several potential benefits, including reduced risk of gastric variceal bleeding, improved portal system hemodynamics in certain patients, and a decrease in portal-systemic shunting. However, risks exist and should be weighed against benefits. Common concerns include procedure-related pain, fever, transient kidney or liver function changes, sclerosant-related complications, and potential worsening of esophageal varices due to altered hemodynamics. A thorough discussion with the care team helps patients understand personalized risk profiles and expected outcomes.
Recovery, Follow-Up, And Long-Term Outcomes
Recovery after BRTO is generally gradual, with most patients able to resume normal activities within a few days to a week, depending on overall health and any comorbid conditions. Post-procedure imaging is standard to verify obliteration and monitor for recanalization or collateral vessel development. Long-term outcomes show BRTO effectively reduces gastric variceal bleeding risk in properly selected patients, though it may alter portal hemodynamics and influence the appearance of esophageal varices. Regular follow-up with hepatology and interventional radiology is essential to manage liver disease and monitor for complications.
Comparing BRTO With Alternatives
In some cases, alternative approaches may be considered, such as transjugular intrahepatic portosystemic shunt (TIPS) or endoscopic therapies. BRTO is often favored when a gastrorenal shunt is present and accessible, and when the aim is direct obliteration of gastric varices with a controlled sclerosant exposure. TIPS can reduce portal pressure systemically but may carry higher risks for encephalopathy in certain patients. Each option has distinct indications, benefits, and caveats, and treatment choice depends on anatomy, liver function, and patient comorbidity.
Key Considerations For Patients And Clinicians
Important considerations include assessing portal hypertension severity, the presence of ascites, liver reserve (e.g., Child-Pugh score), renal function, and potential interactions with other therapies. Patients should be advised on signs of complications, such as fever, abdominal pain, or unusual bleeding, that warrant prompt medical evaluation. Clinicians emphasize careful patient selection, precise procedural technique, and coordinated post-procedure surveillance to optimize safety and effectiveness.
Evidence And Practical Insights
Clinical studies indicate BRTO can substantially reduce recurrent gastric variceal bleeding and improve survival in selected populations with gastric varices and gastrorenal shunts. Practical experience highlights the importance of imaging accuracy, sclerosant dosing, and minimizing balloon dwell time to balance efficacy with safety. Ongoing research continues to compare BRTO directly with alternative therapies and to refine patient selection criteria, sclerosant types, and procedural protocols to enhance outcomes.
Frequently Asked Questions
- Is BRTO painful? Most patients receive anesthesia and experience only mild post-procedural discomfort.
- Can BRTO cause liver function decline? In some cases, minor fluctuations occur; surveillance ensures early detection and management.
- How long does the procedure take? Typical BRTO sessions last 1–3 hours, depending on anatomy and complexity.
- What dedicated follow-up is required? Regular imaging and hepatology visits are common to monitor for recanalization or new variceal developments.
Bottom Line
BRTO provides a targeted, minimally invasive option for managing gastric varices in patients with suitable anatomy, offering meaningful reductions in bleeding risk and favorable outcomes when carefully selected and expertly performed. A collaborative, multidisciplinary approach is essential to optimize patient selection, procedural success, and long-term care.